Skip to main content

Table 1 Clinical and pathological characteristics of patient population

From: Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

   n (%)
No. of patients   45 (100)
Gender; Median age (Min - Max), yrs Female 24 (53.3); 54 (34 - 76)
  Male 21 (46.7); 61 (35 - 75)
ECOG 0 20 (44.4)
  ≥ 1 25 (55.6)
Tumor Location Esophageal 4 (8.9)
  Gastric 19 (42.2)
  Colorectal 22 (48.9)
TNM Stage II 3 (6.7)
  III 12 (26.7)
  IV 30 (66.7)
Treatment Purpose Adjuvant 14 (31.1)
  Palliative 31 (68.9)
Chemotherapy Scheme 5-FU/Cisplatinum 23 (51.1)
  Other* 22 (48.9)
5FU
Mode of Administration
Bolus alone 15 (33.3)
  Bolus + CI# 8 (17.8)
  Continuous infusion 22 (48.9)
  1. *5-FU/LV or 5-FU/FA or FolFOx or FolFIri; #Continous Infusion